DarioHealth (NASDAQ:DRIO) had its target price lowered by equities researchers at Craig Hallum from $20.00 to $12.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s target price would indicate a potential upside of 60.00% from the stock’s current price.
Separately, ValuEngine raised DarioHealth from a “buy” rating to a “strong-buy” rating in a research note on Tuesday.
Shares of NASDAQ:DRIO opened at $7.50 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.70 and a quick ratio of 1.35. DarioHealth has a 12 month low of $3.44 and a 12 month high of $18.60. The stock’s 50 day moving average price is $1.47 and its 200 day moving average price is $0.71.
An institutional investor recently bought a new position in DarioHealth stock. Verition Fund Management LLC purchased a new position in shares of DarioHealth Corp (NASDAQ:DRIO) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 308,334 shares of the company’s stock, valued at approximately $143,000. Verition Fund Management LLC owned about 0.71% of DarioHealth as of its most recent SEC filing.
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.